By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > AI-developed drug will be in trials by year-end, says Google’s Hassabis
News

AI-developed drug will be in trials by year-end, says Google’s Hassabis

News Room
Last updated: 2025/01/21 at 4:27 PM
By News Room
Share
3 Min Read
SHARE

Stay informed with free updates

Simply sign up to the Artificial intelligence myFT Digest — delivered directly to your inbox.

Isomorphic Labs, the four-year old drug discovery start-up owned by Google parent Alphabet, will have an artificial intelligence-designed drug in trials by the end of this year, says its founder Sir Demis Hassabis.

“We’re looking at oncology, cardiovascular, neurodegeneration, all the big disease areas, and I think by the end of this year, we’ll have our first drug,” he said in an interview with the Financial Times at the World Economic Forum.

“It usually takes an average of five to 10 years [to discover] one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,” said Hassabis, who received the Nobel Prize for chemistry with his colleague John Jumper and biochemist David Baker in October.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.

Hassabis previously told the FT his team was working on six drug development programmes with Eli Lilly and Novartis.

In a wide-ranging interview, Hassabis, who is also chief executive of Google DeepMind, said the search giant’s prototype of an AI assistant, known as Project Astra, will probably roll out to consumers later this year. He described a near future, within three years, when there are “billions” of AI agents, “negotiating with each other on behalf of the vendor and the customer” and said it would require a rethinking of the web itself.

He also called for more caution and co-ordination among leading AI developers competing to build artificial general intelligence. He warned the technology could threaten human civilisation if it runs out of control or is repurposed by “bad actors . . . for harmful ends”.

Google DeepMind’s ultimate goal is to create artificial general intelligence, or “a system that is capable of exhibiting all the cognitive capabilities that humans have”, according to Hassabis, who said that despite social media “hype” about it being close, true AGI was still five to 10 years away.

“If something’s possible and valuable to do, people will do it,” Hassabis said. “We’re past that point now with AI, the genie can’t be put back in the bottle . . . so we have to try and make sure to steward that into the world in as safe a way as possible.”

Read the full article here

News Room January 21, 2025 January 21, 2025
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
AI won’t take your job – but someone using it will

Watch full video on YouTube

Could Crypto-Backed Mortgages Put The U.S. Housing Market At Risk?

Watch full video on YouTube

Aurubis AG (AIAGY) Q4 2025 Earnings Call Transcript

FollowPlay Earnings CallPlay Earnings Call Aurubis AG (OTCPK:AIAGY) Q4 2025 Earnings Call…

A bartenders’ guide to the best cocktails in Washington

This article is part of FT Globetrotter’s guide to Washington DCWashington is…

Dan Ives: Tesla’s “golden” chapter includes AI, robots, and Robotaxi scale.

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

News

Aurubis AG (AIAGY) Q4 2025 Earnings Call Transcript

By News Room
News

A bartenders’ guide to the best cocktails in Washington

By News Room
News

C3.ai, Inc. 2026 Q2 – Results – Earnings Call Presentation (NYSE:AI) 2025-12-03

By News Room
News

Stephen Witt wins FT and Schroders Business Book of the Year

By News Room
News

Verra Mobility Corporation (VRRM) Presents at UBS Global Technology and AI Conference 2025 Transcript

By News Room
News

Zara clothes reappear in Russia despite Inditex’s exit

By News Room
News

U.S. Stocks Stumble: Markets Catch A Cold To Start December

By News Room
News

Apple replaces head of AI with executive poached from Microsoft

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?